Literature DB >> 25117730

Defined serum- and xeno-free cryopreservation of mesenchymal stem cells.

Shahla Hamza Al-Saqi1, Mohammed Saliem, Hernan Concha Quezada, Åsa Ekblad, Aino Fianu Jonasson, Outi Hovatta, Cecilia Götherström.   

Abstract

Mesenchymal stem cells (MSCs) have vast potential in cell therapy, and are experimentally used in the clinic. Therefore, it is critical to find a serum- and xeno-free cryopreservation method. The aim of this study was to compare two serum- and xeno-free cryoprotectants for MSCs. Adipose tissue MSCs (Ad-MSCs) and bone marrow MSCs (BM-MSCs) were cryopreserved in two cryoprotectants: the defined serum- and xeno-free STEM-CELLBANKER™ (CB) and 10 % dimethyl sulfoxide (DMSO) in a xeno-free serum replacement cell culture medium and compared to non-cryopreserved MSCs. MSCs cryopreserved in CB or DMSO had similar morphology and surface marker expression compared to their respective non-cryopreserved MSC. Ad-MSCs and BM-MSC in both cryoprotectant media exhibited reduced mean fluorescence intensity (MFI) for CD105, BM-MSCs for CD73 and Ad-MSC increased MFI for HLA class I compared to non-cryopreserved MSCs. Population doubling time of CB cryopreserved and non-cryopreserved Ad-MSCs was similar (38.1 ± 13.6 and 36.8 ± 12.1 h), but somewhat higher when cryopreserved in DMSO (42.2 ± 10.8 h). BM-MSCs had higher population doubling time (CB 47.7 ± 11.4 and DMSO 62.3 ± 32.9 h respectively, p < 0.05) compared to Ad-MSCs. The viability of Ad-MSCs was significantly higher after cryopreservation in CB compared to DMSO (90.4 ± 4.5 % vs. 79.9 ± 3.8 % respectively). Ad-MSCs and BM-MSCs retained their mesodermal differentiation potential when cryopreserved in both cryoprotectants. The characteristics of Ad-MSCs post-thawing are better preserved by CB than by DMSO in serum- and xeno-free medium. Furthermore, Ad-MSCs and BM-MSCs are differently affected by the cryoprotectants, which may have implications for cell therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25117730     DOI: 10.1007/s10561-014-9463-8

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  16 in total

1.  Acceleration of diabetic wound healing by a cryopreserved living dermal substitute created by micronized amnion seeded with fibroblasts.

Authors:  Yongjun Zheng; Shizhao Ji; Haibin Wu; Song Tian; Xingtong Wang; Pengfei Luo; He Fang; Zhihong Wang; Junjie Wang; Zhongshan Wang; Shichu Xiao; Zhaofan Xia
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

Review 2.  Recent Advances in Tissue Engineering Strategies for the Treatment of Joint Damage.

Authors:  Makeda K Stephenson; Ashley L Farris; Warren L Grayson
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

3.  Evaluation of Serum-Free, Xeno-Free Cryopreservation Solutions for Human Adipose-Derived Mesenchymal Stem Cells.

Authors:  Chika Miyagi-Shiohira; Naoya Kobayashi; Issei Saitoh; Masami Watanabe; Yasufumi Noguchi; Masayuki Matsushita; Hirofumi Noguchi
Journal:  Cell Med       Date:  2016-09-01

4.  Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.

Authors:  Zyrafete Kuçi; Halvard Bönig; Hermann Kreyenberg; Milica Bunos; Anna Jauch; Johannes W G Janssen; Marijana Škifić; Kristina Michel; Ben Eising; Giovanna Lucchini; Shahrzad Bakhtiar; Johann Greil; Peter Lang; Oliver Basu; Irene von Luettichau; Ansgar Schulz; Karl-Walter Sykora; Andrea Jarisch; Jan Soerensen; Emilia Salzmann-Manrique; Erhard Seifried; Thomas Klingebiel; Peter Bader; Selim Kuçi
Journal:  Haematologica       Date:  2016-05-12       Impact factor: 9.941

Review 5.  Cryopreservation of Adipose-Derived Mesenchymal Stem Cells.

Authors:  Chika Miyagi-Shiohira; Kiyoto Kurima; Naoya Kobayashi; Issei Saitoh; Masami Watanabe; Yasufumi Noguchi; Masayuki Matsushita; Hirofumi Noguchi
Journal:  Cell Med       Date:  2015-08-26

6.  Xeno-free protocol for GMP-compliant manufacturing of human fetal pancreas-derived mesenchymal stem cells.

Authors:  Zahra Jabbarpour; Sajjad Aghayan; Babak Arjmand; Khadijeh Fallahzadeh; Sepideh Alavi-Moghadam; Bagher Larijani; Hamid Reza Aghayan
Journal:  Stem Cell Res Ther       Date:  2022-06-21       Impact factor: 8.079

7.  Influence of Factors of Cryopreservation and Hypothermic Storage on Survival and Functional Parameters of Multipotent Stromal Cells of Placental Origin.

Authors:  Denys Pogozhykh; Volodymyr Prokopyuk; Olena Pogozhykh; Thomas Mueller; Olga Prokopyuk
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

Review 8.  Mesenchymal stromal cells as a potential therapeutic for neurological disorders.

Authors:  Takeo Mukai; Arinobu Tojo; Tokiko Nagamura-Inoue
Journal:  Regen Ther       Date:  2018-08-24       Impact factor: 3.419

Review 9.  Perspectives for Clinical Translation of Adipose Stromal/Stem Cells.

Authors:  Mimmi Patrikoski; Bettina Mannerström; Susanna Miettinen
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

10.  Canine and Equine Mesenchymal Stem Cells Grown in Serum Free Media Have Altered Immunophenotype.

Authors:  Kaitlin C Clark; Amir Kol; Salpi Shahbenderian; Jennifer L Granick; Naomi J Walker; Dori L Borjesson
Journal:  Stem Cell Rev Rep       Date:  2016-04       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.